MedElevator Войти в исследования
← Поиск публикаций

DOI 10.3389/fimmu.2025.1736606

Медицинская библиотека · Frontiers in immunology · 2026

IL-6/STAT3 signaling in prostate cancer: CAF-driven immune evasion and therapeutic opportunities.

Zhou Tao, Li Yuqi, Liu Zhiyu, Zeng Zhiqiang, Li Tao, Chen Li, Zhao Huan, Wu Xiaochun, Shen Yuxuan, Fan Haitao, Zhu Xiaoxiao, Zhou Yubo, Zou Lunhong, Zhao Dan

СтатьяОбзорПеревод в очереди

Аннотация

Interleukin-6 (IL-6) plays a pivotal regulatory role in prostate cancer progression, contributing to therapy resistance and reshaping of the tumor microenvironment. This review outlines the clinical relevance of IL-6 as a potential prognostic biomarker and describes its mechanistic involvement in the development of castration resistance, with emphasis on its interplay with distinct cancer-associated fibroblast (CAF) subtypes. Elevated serum IL-6 levels in metastatic castration-resistant prostate cancer are associated with poor responses to docetaxel, enzalutamide, or abiraterone, and correlate with worse prognosis. Mechanistically, IL-6 promotes neuroendocrine differentiation and sustains cell survival under therapeutic stress through activation of signal transducer and activator of transcription 3 (STAT3), mitogen-activated protein kinase (MAPK), and androgen receptor signaling pathways. Recent single-cell studies reveal that prostate CAFs are highly heterogeneous. Certain subtypes are linked to extracellular matrix remodeling and fibrosis, while others exhibit inflammatory or immune-modulatory characteristics, differentially influencing tumor evolution. Specific CAF subsets have been strongly implicated in promoting castration resistance and adverse outcomes. Therapeutic strategies targeting the IL-6/IL-6R axis-such as neutralizing antibodies, advanced chimeric antigen receptor (CAR)-T designs, and combination regimens-are under active investigation. Simultaneously, modulating CAF plasticity to convert tumor-promoting phenotypes into tumor-restraining ones represents a promising therapeutic avenue. A deeper understanding of IL-6 functions across CAF subtypes may unlock novel precision therapy opportunities for prostate cancer.

Для цитирования: Zhou Tao, Li Yuqi, Liu Zhiyu, Zeng Zhiqiang, Li Tao, Chen Li, Zhao Huan, Wu Xiaochun, Shen Yuxuan, Fan Haitao, Zhu Xiaoxiao, Zhou Yubo, Zou Lunhong, Zhao Dan. IL-6/STAT3 signaling in prostate cancer: CAF-driven immune evasion and therapeutic opportunities.. Frontiers in immunology. 2026. DOI: 10.3389/fimmu.2025.1736606.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.